Pfizer carefully proposed two plans in 2014 and tried to negotiate for reducing the company’s corporate tax rate and its further expansion into global markets. First it was through corporate conversion including a high profile merger plan for 100 $ billion with UK-based ‘Astra- Zeneca’ whereby the headquarters of the American pharmaceutical giant would be moved from New York to London. Another proposed agreement was through the merger with Ireland based ‘Allegan’. Both proposals never took shape and were strongly criticized by the US Government, local communities, and various stakeholders. The company’s experience highlights some of the problems that can arise in even the best- considered consolidations in the ever-changing pharmaceutical industry.
Keywords: Pfizer, merger, global markets.